These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 3842691)

  • 41. Postmarket surveillance for drug-eluting coronary stents: a comprehensive approach.
    Baim DS; Mehran R; Kereiakes DJ; Gross TP; Simons M; Malenka D; Kaplan AV
    Circulation; 2006 Feb; 113(6):891-7. PubMed ID: 16476863
    [No Abstract]   [Full Text] [Related]  

  • 42. [Seventh French Drug Surveillance Seminar. Caen, 21-22 November 1985].
    Therapie; 1986; 41(5):323-84. PubMed ID: 3810518
    [No Abstract]   [Full Text] [Related]  

  • 43. [Eighth French Drug Surveillance Seminar. Paris, 23-24 October 1986].
    Therapie; 1987; 42(4):331-410. PubMed ID: 3686465
    [No Abstract]   [Full Text] [Related]  

  • 44. Postmarketing surveillance.
    Oleen MA
    Can J Hosp Pharm; 1987 Oct; 40(5):171-2, 179-80. PubMed ID: 10284449
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Methods for improving the reporting of adverse effects.
    Prescrire Int; 2011 Mar; 20(114):71. PubMed ID: 21648229
    [No Abstract]   [Full Text] [Related]  

  • 46. Collection and analysis of drug safety data in pregnancy.
    Moretti M
    Can J Clin Pharmacol; 2007; 14(1):e34-6. PubMed ID: 17213508
    [No Abstract]   [Full Text] [Related]  

  • 47. [6th French seminar on drug surveillance. Clermont-Ferrand, 22-23 November 1984].
    Therapie; 1985; 40(5):287-376. PubMed ID: 4095682
    [No Abstract]   [Full Text] [Related]  

  • 48. [Comprehensive detection of severe, potentially life-threatening drug side effects].
    Schönhöfer PS; Wessely-Stickel B; Schulte-Sasse H; Werner W
    Verh Dtsch Ges Inn Med; 1989; 95():687-90. PubMed ID: 2603504
    [No Abstract]   [Full Text] [Related]  

  • 49. [How to assess the risk of drugs?].
    Roujeau JC
    Ann Dermatol Venereol; 1998 Oct; 125(10):673-5. PubMed ID: 9835953
    [No Abstract]   [Full Text] [Related]  

  • 50. Adverse drug reaction monitoring: doing it the French way.
    Moore N; Biour M; Paux G; Loupi E; Begaud B; Boismare F; Royer RJ
    Lancet; 1985 Nov; 2(8463):1056-8. PubMed ID: 2865527
    [No Abstract]   [Full Text] [Related]  

  • 51. Adverse reaction assessment in Thailand.
    Sriwatanakul K; Pothisiri P
    Med Toxicol; 1986; 1 Suppl 1():105-9. PubMed ID: 3821423
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Review of Canadian pharmacist involvement in adverse drug reaction reporting.
    Taras-Zasowski KM; Einarson TR
    Can J Hosp Pharm; 1989 Jun; 42(3):105-8, 133. PubMed ID: 10318271
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [How to report side-effects of drugs?].
    Guillaume JC
    Ann Dermatol Venereol; 1986; 113(4):375-6. PubMed ID: 3767239
    [No Abstract]   [Full Text] [Related]  

  • 54. [Detection of drug side effects at the Heidelberg Medical Clinic].
    Jacubeit T; Drisch D
    Verh Dtsch Ges Inn Med; 1989; 95():690-3. PubMed ID: 2603505
    [No Abstract]   [Full Text] [Related]  

  • 55. [Bayesian approach to the imputability of undesirable phenomena to drugs].
    Auriche M
    Therapie; 1985; 40(5):301-6. PubMed ID: 4095686
    [No Abstract]   [Full Text] [Related]  

  • 56. Possible strategies for early recognition of potential drug safety problems.
    Venulet J
    Adverse Drug React Acute Poisoning Rev; 1988; 7(1):39-47. PubMed ID: 3389236
    [No Abstract]   [Full Text] [Related]  

  • 57. Current French system of post-marketing drug surveillance.
    Albengres E; Gauthier F; Tillement JP
    Int J Clin Pharmacol Ther Toxicol; 1990 Jul; 28(7):312-4. PubMed ID: 2387656
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [A network of regional correspondents for studying undesirable effects].
    Haramburu F; Péré JC; Begaud B; Albin H
    Therapie; 1985; 40(5):321-4. PubMed ID: 4095688
    [No Abstract]   [Full Text] [Related]  

  • 59. [Sensitivity and specificity of imputability criteria. Study and comparison of these efficacity indices for 7 methods].
    Péré JC; Godin MH; Bégaud B; Haramburu F; Albin H
    Therapie; 1985; 40(5):307-12. PubMed ID: 4095687
    [No Abstract]   [Full Text] [Related]  

  • 60. [Drug surveillance as seen by the general practitioner. Apropos of a survey of 4175 physicians].
    Begaud B; Haramburu F; Péré JC; Delmas N; Lorson B; Albin H
    Therapie; 1984; 39(5):453-7. PubMed ID: 6506000
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.